BioIncubator - our Pipeline
With disruptive Innovations into the Future
The BRAINBioIncubator comprises promising R&D projects with high value creation potential. The developments are carried out in-house or together with industry partners.
Current pipeline projects
| Project | Description | Status |
|---|---|---|
|
Deucrictibant as |
The compound Deucrictibant (former name: PHA121) has been identified and characterized at our research site in Potsdam, Germany (AnalytiCon Discovery), and has been licensed to Pharvaris N.V. (Nasdaq: PHVS). The compound for the treatment of bradykinin-mediated diseases as HAE is currently in clinical development. |
|
|
Enzyme for wound healing |
Aurase® is an enzymatic compound developed by BRAIN Biotech for the cleansing of chronic wounds. SolasCure Ltd., a company founded with the participation of BRAIN Biotech, is working on the registration of this medical compound. Initial clinical development has yielded promising data demonstrating the enzyme's great potential as a clinically effective means of debridement (removal of infected and non-viable tissue) and its safe application. The compound has successfully completed phase 2a clinical trials. SolasCure is currently preparing for phase 2b/3 clinical development and is in the process of financing further business activities. |
SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel |
|
Gold recovery |
Development of microorganisms and a bioprocess for the environmentally friendly recovery of gold. |
Upscaling process with industrial partner. |
|
G-dase® E / G-dase® M |
These enzymes are proprietary CRISPR nucleases developed by BRAIN Biotech AG to build a genome editing technology platform. The development of G-dase® E is aimed, among other things, at a new type of cancer therapy. Both nucleases can also be used for gene editing in industrial biotechnology. |
BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology |
